HEALTHCARE RESOURCE UTILIZATION AND REAL-WORLD DISEASE BURDEN AMONG PATIENTS WITH PD-L1-POSITIVE METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN THE FIRST-LINE SETTING
Author(s)
Nandita Kachru, MS, PhD1, Aiza Malik, MSc2, Kaori L. Ito, PhD3, Katherine Stang, PharmD4, Maryam Afshari, PharmD4, Brian Stwalley, BS, PharmD4, Adam Brufsky, MD5.
1Gilead Sciences Inc., Foster City, CA, USA, 2Tempus AI, Inc., Chicago, IL, USA, 3Tempus AI, Inc, Rolling Hills Estates, CA, USA, 4Gilead Sciences, Inc., Foster City, CA, USA, 5University of Pittsburgh / UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
1Gilead Sciences Inc., Foster City, CA, USA, 2Tempus AI, Inc., Chicago, IL, USA, 3Tempus AI, Inc, Rolling Hills Estates, CA, USA, 4Gilead Sciences, Inc., Foster City, CA, USA, 5University of Pittsburgh / UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
OBJECTIVES: To describe healthcare resource utilization (HCRU) and disease burden in patients with PD-L1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC) in the first-line (1L) setting.
METHODS: This retrospective cohort study analyzed de-identified mTNBC patient records linked to claims using the Tempus Lens Platform (Tempus AI, Inc., Chicago, IL). Adults with PD-L1+ mTNBC initiating 1L therapy between January 2018 and June 2024 (index date) were included. Patients were followed from index to death, last record, or study end (June 2025), with ≥3 months follow-up required if alive. Treatment patterns were described. Real-world overall survival (rwOS), progression-free survival (rwPFS), time to next treatment or death (rwTTNTD), and time on treatment (rwToT) were estimated using Kaplan-Meier methods with risk-set adjustment for left truncation. All-cause HCRU was reported per-patient-per-month (PPPM) in a subset with continuous claims enrollment.
RESULTS: 161 patients with PD-L1+ mTNBC were included (mean age, 57.8 years; 82 [51%] had recurrent disease, and 9 [11%] received pembrolizumab in the early setting; median follow-up, 19.3 months). Of 161 patients who received 1L treatment, 24 (15%) received chemotherapy monotherapy, 21 (13%) chemotherapy combinations, and 113 (70%) immunotherapy-based regimens. Among 106 patients who received subsequent lines of therapy, sacituzumab govitecan was used in 2L for 25 (24%) patients and in 3L for 27 (25%) patients. Of patients who received 1L treatment, median rwOS was 22.4 months, rwPFS was 6.4 months, rwTTNTD was 9.2 months, and rwToT was 3.8 months. Among 72 patients eligible for all-cause HCRU analyses, there were 0.51 hospitalizations, 0.11 emergency room visits, 2.22 outpatient medical visits, and 2.99 office visits PPPM.
CONCLUSIONS: Patients with PD-L1+ mTNBC experienced suboptimal outcomes and high HCRU, characterized by routine care and high utilization of hospital-administered immunotherapy, underscoring a substantial unmet need in this population.
METHODS: This retrospective cohort study analyzed de-identified mTNBC patient records linked to claims using the Tempus Lens Platform (Tempus AI, Inc., Chicago, IL). Adults with PD-L1+ mTNBC initiating 1L therapy between January 2018 and June 2024 (index date) were included. Patients were followed from index to death, last record, or study end (June 2025), with ≥3 months follow-up required if alive. Treatment patterns were described. Real-world overall survival (rwOS), progression-free survival (rwPFS), time to next treatment or death (rwTTNTD), and time on treatment (rwToT) were estimated using Kaplan-Meier methods with risk-set adjustment for left truncation. All-cause HCRU was reported per-patient-per-month (PPPM) in a subset with continuous claims enrollment.
RESULTS: 161 patients with PD-L1+ mTNBC were included (mean age, 57.8 years; 82 [51%] had recurrent disease, and 9 [11%] received pembrolizumab in the early setting; median follow-up, 19.3 months). Of 161 patients who received 1L treatment, 24 (15%) received chemotherapy monotherapy, 21 (13%) chemotherapy combinations, and 113 (70%) immunotherapy-based regimens. Among 106 patients who received subsequent lines of therapy, sacituzumab govitecan was used in 2L for 25 (24%) patients and in 3L for 27 (25%) patients. Of patients who received 1L treatment, median rwOS was 22.4 months, rwPFS was 6.4 months, rwTTNTD was 9.2 months, and rwToT was 3.8 months. Among 72 patients eligible for all-cause HCRU analyses, there were 0.51 hospitalizations, 0.11 emergency room visits, 2.22 outpatient medical visits, and 2.99 office visits PPPM.
CONCLUSIONS: Patients with PD-L1+ mTNBC experienced suboptimal outcomes and high HCRU, characterized by routine care and high utilization of hospital-administered immunotherapy, underscoring a substantial unmet need in this population.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE539
Topic
Clinical Outcomes, Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology